Duration of Dual Antiplatelet Therapy After ACS: A Moving Target – MM1702
Acute coronary syndrome (ACS) remains the major cause of morbidity and mortality worldwide.
Secondary prevention through lifestyle changes and pharmacotherapy remains pivotal to reduction. Aspirin
has improved outcomes in patients presenting with ACS. (CURE) trial was a landmark study showing improved
outcomes in an ACS cohort treated with aspirin and clopidogrel compared with aspirin alone. Inherent in
the use of more potent platelet inhibitors is a degree of obligate bleeding. Contemporary antiplatelet agents
probably provide maximal platelet inhibition with tolerable, safe bleeding in most patients for six to 12 months after
ACS.
Modern Medicine – February 2017
